Mirum Pharmaceuticals, Inc.
Financials
Valuation Metrics
Mirum Pharmaceuticals, Inc.'s Market Cap is $5.96B. At end of 2025 it was $3.97B. Ranked #1173 of 3,121 in US market (top 38%), #390 of 1,463 on NASDAQ (top 27%), #66 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.96B | US#1,173/3,121 Sec#66/266 |
| Revenue | $618M | US#2,167/3,121 Sec#70/266 |
| Net Income | $-860M | US—/3,121 Sec—/266 |
| Total Assets | $1.04B | US#2,464/3,121 Sec#102/266 |
| Net Assets | $-10M | US#2,929/3,121 Sec#245/266 |
| Employees | 418 | US#2,328/3,121 Sec#90/266 |
| Value | ||
| P/S | 9.65x | US#2,701/3,121 Sec#114/266 |
| FCF Yield | -3.84% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -82.32% | US#3,047/3,121 Sec#247/266 |
| Op. Margin | -17.42% | US#2,593/3,121 Sec#99/266 |
| Revenue Growth | 44.02% | US#270/3,121 Sec#52/266 |
| Financial Health | ||
| Total Debt | $761M | US#1,683/3,121 Sec#52/266 |
| FCF | $-229M | US#2,802/3,121 Sec#218/266 |
| Cash | $331M | US#1,353/3,121 Sec#77/266 |
| Current Ratio | 2.86x | US#847/3,121 Sec#200/266 |
| Performance | ||
| 1Y Return | 21.92% | US#802/3,121 Sec#131/266 |
| 1M Return | -10.18% | US#1,220/3,121 Sec#112/266 |
| From 52W High | -29.36% | US#1,741/3,121 Sec#132/266 |
| 1Y MDD | -28.58% | US#1,184/3,121 Sec#68/266 |
| Trading | ||
| Volume | 1,511,157 shares | US#1,715/3,121 Sec#182/266 |
| Trading Value | $142M | US#1,057/3,121 Sec#78/266 |
| Per Share | ||
| EPS | $-13.25 | US—/3,121 Sec—/266 |
| BPS | $-0.16 | US—/3,121 Sec—/266 |
Company Info
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.